Table 1.

Questions included in the survey of US rheumatologists. Possible responses are listed in parentheses.

1.	In which region of the country do you practice?
	(Southwest; Northwest; Midwest; Southeast; Mid-Atlantic; Northeast; Alaska/Hawaii; International)
2.	What is your gender?
	(male/female)
3.	In which type of practice do you work?
	(academic; hospital-based; solo private practice; group specialty practice; other)
4.	Including fellowship, for how many years have you been practicing rheumatology?
	(< 5 yrs; 5–10 yrs; 10–15 yrs; 15–20 yrs; > 20 yrs)
5.	On average, approximately how many patients with a rheumatologic diagnosis do you see each week?
	(< 5 pts; 5–10 pts; 10–15 pts; > 20 pts)
6.	Approximately what percentage of the patients you care for are managed on chronic glucocorticoids?
	(< 10%; 10–25%; 25–50%; 50–75%; 75–90%; > 70%)
7.	Approximately what percentage of the patients you care for are managed on other immunosuppressive agents, including cyclophosphamide, methotrexate, azathioprine, and mycophenolate?
	(< 10%; 10–25%, 25–50%; 50–75%; 75–90%; > 90%)
8.	Have any of your patients ever developed Pneumocystis jirovecii pneumonia (PCP)?
	(no; yes; if yes, please specify how many)
9.	Do you prescribe chemoprophylaxis for PCP? If yes, please specify what prophylaxis method you prefer.
	(no; yes – with trimethoprim/sulfamethoxazole once daily; yes – with trimethoprim/sulfamethoxazole 3 times per week; yes – with aerosolized pentamidine; yes – with another prophylactic medication. Please specify)
10.	For which underlying conditions are you most likely to prescribe PCP chemoprophylaxis? (mark all that apply)
	(systemic lupus erythematosus; rheumatoid arthritis; psoriatic arthritis; Wegener’s granulomatosis; polyarteritis nodosa; microscopic polyangiitis; other systemic vasculitides; scleroderma; dermatomyositis; polymyositis; other myositis; other. Please specify; rheumatologic diagnosis does not affect my decision to prescribe or not prescribe PCP chemoprophylaxis; I do not prescribe PCP chemoprophylaxis)
11.	With which treatment regimens are you likely to prescribe PCP chemoprophylaxis? (mark all that apply)
	(prednisone alone; prednisone in combination with another immunosuppressant agent; methotrexate; cyclophosphamide; azathioprine; mycophenolate; TNF-alpha inhibitors; cyclosporine; 6-mercaptopurine; rituximab; other. Please specify; treatment regimen does not affect my decision to prescribe or not prescribe PCP chemoprophylaxis)
12.	At what dose of prednisone are you likely to prescribe PCP chemoprophylaxis?
	(≥ 5 mg/day; ≥ 10 mg/day; ≥ 15 mg/day; ≥ 20 mg/day; ≥ 30 mg/day; ≥ 40 mg/day; ≥ 50 mg/day; other. Please specify; prednisone dosage does not affect my decision to prescribe or not prescribe PCP chemoprophylaxis; I do not prescribe PCP chemoprophylaxis)
13.	What laboratory data do you use when deciding whether to prescribe PCP chemoprophylaxis? (please mark all that apply)
	(peripheral blood absolute lymphocyte count; peripheral blood CD4 T cell count; other. Please specify; laboratory data does not affect my decision to prescribe or not prescribe PCP chemoprophylaxis; I do not prescribe PCP chemoprophylaxis)
14.	What other clinical data not mentioned above makes you more likely to prescribe PCP chemoprophylaxis? (please mark all that apply)
	(history of PCP; history of other opportunistic infection; history of interstitial pulmonary fibrosis; other. Please specify; other clinical data does not affect my decision to prescribe or not prescribe PCP chemoprophylaxis; I do not prescribe PCP chemoprophylaxis)
15.	What is the most important factor in your decision as to whether or not to prescribe PCP chemoprophylaxis?
	(underlying condition; treatment regimen; dose of medication; laboratory data; history of PCP; history of other opportunistic infections; history of interstitial pulmonary fibrosis; other. Please specify; I do not prescribe PCP chemoprophylaxis)